StockNews.com Initiates Coverage on Aptevo Therapeutics (NASDAQ:APVO)

Investment analysts at StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm lowered their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 23rd.

Aptevo Therapeutics Price Performance

NASDAQ APVO opened at $0.21 on Friday. The company has a 50 day simple moving average of $0.23 and a 200-day simple moving average of $0.44. Aptevo Therapeutics has a 52-week low of $0.14 and a 52-week high of $10.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission. 8.06% of the stock is owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.